Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Receivables: 2021-2024

Historic Receivables for Tg Therapeutics (TGTX) over the last 3 years, with Dec 2024 value amounting to $152.7 million.

  • Tg Therapeutics' Receivables rose 129.32% to $265.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $839.7 million, marking a year-over-year increase of 156.16%. This contributed to the annual value of $152.7 million for FY2024, which is 167.90% up from last year.
  • As of FY2024, Tg Therapeutics' Receivables stood at $152.7 million, which was up 167.90% from $57.0 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Receivables registered a high of $152.7 million during FY2024, and its lowest value of $1.4 million during FY2021.
  • Over the past 2 years, Tg Therapeutics' median Receivables value was $104.8 million (recorded in 2023), while the average stood at $104.8 million.
  • Data for Tg Therapeutics' Receivables shows a peak YoY soared of 167.90% (in 2024) over the last 5 years.
  • Over the past 3 years, Tg Therapeutics' Receivables (Yearly) stood at $1.4 million in 2021, then reached $57.0 million in 2023, then surged by 167.90% to $152.7 million in 2024.